Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Respiratory Care Devices Market
The respiratory care devices market is driven by the rising prevalence of chronic respiratory diseases such as COPD, asthma, and sleep apnea, compounded by an aging global population and increasing air pollution. Technological advancements, including portable and user-friendly devices, have improved patient compliance and expanded adoption. The COVID-19 pandemic underscored the critical need for respiratory care, accelerating demand for ventilators, oxygen concentrators, and related equipment.
Favorable healthcare spending, supportive reimbursement policies, and growing public awareness of respiratory health further propel market growth. The market is segmented by product type, disease indication, end user, and region, with North America currently leading due to advanced healthcare infrastructure and higher medical expenditures.
Market size
Growth trajectory through 2035
Respiratory Care Devices Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 Technological Innovations
- Introduction of smart inhalers, advanced nebulizers, and AI-integrated respiratory devices to improve patient outcomes and device usability.
-
2015 Strategic Acquisitions
- BD’s acquisition of CareFusion for $12.2 billion in 2015 expanded its respiratory care portfolio, including ventilators and monitoring devices.
-
2025 Regulatory Approvals
- Faster approval processes for respiratory devices post-2025, particularly for home healthcare applications.
-
Development 04 Partnerships and Collaborations
- Collaborations between device manufacturers and digital health platforms to integrate remote monitoring and telehealth capabilities into respiratory care.
Emerging opportunities added
- Home healthcare expansion Growing trend toward home-based respiratory care creates demand for portable and smart devices.
- Technological integration AI and remote monitoring capabilities in respiratory devices offer opportunities for innovation and improved patient outcomes.
- Emerging markets growth Increasing healthcare spending and awareness in Latin America, the Middle East, and Asia-Pacific regions present untapped market potential.
- Infection control focus Heightened emphasis on disposable and single-use respiratory products supports market expansion in hospitals and clinics.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $25.89 Bn
- CAGR
- 8.80%
- Expansion
- 2.3×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- user-friendly devices
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Regulatory and approval delays
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Technological Innovations: Introduction of smart inhalers, advanced nebulizers, and AI-integrated respiratory devices to improve patient outcomes and device usability
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 139-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Respiratory Care Devices Market today ($25.89 Bn base), and how fast will it grow at 8.8% CAGR through 2035?
- Which of Therapeutic Devices: Includes ventilators, masks, PAP devices and other tracked segments holds the largest share, and how do the growth rates diverge?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Respironics, ResMed Inc, Fisher & Paykel Healthcare and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of respiratory diseases) and top restraints (led by Regulatory and approval delays), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of respiratory diseases Chronic conditions such as COPD, asthma, and sleep apnea are increasing due to pollution, lifestyle changes, and tobacco use, driving demand for diagnostic and therapeutic devices.
- Technological advancements Development of portable, user-friendly, and wirelessly enabled devices enhances patient compliance and broadens market access.
- Impact of COVID-19 pandemic Highlighted the critical need for respiratory care, leading to increased demand for ventilators, oxygen concentrators, and related equipment.
- Healthcare spending and reimbursement policies Rising medical expenditures and supportive reimbursement frameworks promote adoption of advanced respiratory care solutions.
- Aging population Older adults are more susceptible to respiratory conditions, contributing to sustained market growth.
- Public awareness and early diagnosis Growing emphasis on respiratory health and early intervention improves disease management and device utilization.
Restraints
Holding it back
- Regulatory and approval delays Extended timelines for product approvals post-2025 may slow market entry for new devices.
- Supply chain disruptions Shortages of essential components and high maintenance costs for devices pose operational challenges.
- High device costs Advanced respiratory care devices remain expensive, limiting accessibility in lower-income regions.
- Limited healthcare infrastructure Insufficient healthcare facilities and trained personnel in emerging markets restrict market penetration.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of respiratory diseases | +4.0% | Global | 2025–2035 |
| Technological advancements | +2.5% | Global | 2025–2035 |
| Impact of COVID-19 pandemic | +1.9% | Global | 2025–2035 |
| Healthcare spending and reimbursement policies | +1.3% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory and approval delays | −1.6% | Global | 2025–2029 |
| Supply chain disruptions | −1.1% | Global | 2025–2029 |
| High device costs | −0.8% | Global | 2025–2029 |
The respiratory care devices market is segmented by product type, disease indication, end user, and region.
Revenue share by type · 2025 base year
% OF $25.89 BN RESPIRATORY CARE DEVICES MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $25.89 Bn Respiratory Care Devices Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Therapeutic Devices: Includes ventilators
-
masks
-
PAP devices
-
inhalers
-
nebulizers.Monitoring Devices: Includes pulse oximeters
-
circuits
-
filters
By end-user industry
-
user-friendly devices
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $25.89 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~46.5% in 2025. Dominates the market due to advanced healthcare infrastructure, high healthcare spending, and strong reimbursement policies. The U.S. is a critical market driver, with rising prevalence of asthma, CO…
Per-region detail
-
North America
Dominates the market due to advanced healthcare infrastructure, high healthcare spending, and strong reimbursement policies. The U.S. is a critical market driver, with rising prevalence of asthma, COPD, and sleep apnea
-
Europe
Focuses on healthcare quality and patient safety, contributing to steady market growth. Aging populations and increasing respiratory disease incidence support demand
-
Asia-Pacific
Experiencing rapid growth due to rising healthcare spending, increasing awareness of respiratory health, and a growing aging population. Countries such as China and India are key contributors
-
Latin America
Market expansion is driven by rising medical expenditures and growing adoption of advanced respiratory care solutions
-
Middle East & Africa
Increasing healthcare investments and awareness of respiratory diseases are gradually boosting market penetration
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The respiratory care devices market is highly competitive, with leading players focusing on innovation, strategic partnerships, and geographic expansion to strengthen their market position.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Respironics
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
ResMed Inc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Fisher & Paykel Healthcare
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Vyaire Medical
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Getinge AB
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Draegerwerk AG
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Air Liquide Healthcare
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Linde Healthcare
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Respiratory Care Devices Market in 2025?
The Respiratory Care Devices Market is estimated at approximately $25.89 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 8.80% CAGR from 2025 to 2035, reaching $60.18 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
North America leads the market, accounting for approximately 46.5% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Therapeutic Devices leads the type segmentation with an estimated 40.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Philips Respironics, ResMed Inc, Fisher & Paykel Healthcare, Vyaire Medical, Getinge AB, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Rising prevalence of respiratory diseases. Chronic conditions such as COPD, asthma, and sleep apnea are increasing due to pollution, lifestyle changes, and tobacco use, driving demand for diagnostic and therapeutic devices.
-
What are the main restraints?
The primary restraint is Regulatory and approval delays. Extended timelines for product approvals post-2025 may slow market entry for new devices.
-
What are the most recent developments?
Recent notable events include: : Technological Innovations: Introduction of smart inhalers, advanced nebulizers, and AI-integrated respiratory devices to improve patient outcomes and device usability; 2015: Strategic Acquisitions: BD’s acquisition of CareFusion for $12.2 billion in 2015 expanded its respiratory care portfolio, including ventilators and monitoring devices; 2025: Regulatory Approvals: Faster approval processes for respiratory devices post-2025, particularly for home healthcare applications. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Respiratory Care Devices Market is projected to reach $60.18 Bn by 2035, up from $25.89 Bn in 2025 — a 8.80% CAGR equating to roughly 2.3× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.